CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ultivue announces the addition of two new executive team members in order to help strengthen its position as a leading assay development solutions provider for multiplex biomarker analysis.
Keith Wharton MD PhD has recently joined Ultivue in the role of Vice President, Medical Director, and James (Bud) Drummey has joined as Vice President, Manufacturing Operations and Quality.
Keith is a board-certified anatomic pathologist with diverse achievements in research and drug/diagnostic development. Leading Ultivue’s assay services laboratory, he brings expertise in investigative pathology, microscopy and imaging, and digital pathology. Most recently he was Senior Medical Director of Leica Biosystems, and prior to that he led and supported R&D, toxicology, biomarker, and clinical study teams in multiple therapeutic areas at Novartis and Biogen.
According to Keith, “Rapid progress in the fields of immuno-oncology and single cell profiling are creating an urgency around multiplex investigations with single cell resolution that retain tissue context. Ultivue’s DNA barcode-based multiplex technology accelerates research assay development and performance times as researchers and biopharma companies strive to identify disease drivers and create new targeted therapies.”
Bud brings to Ultivue 20+ years of leadership experience in large-scale and start-up consumables reagent manufacturing operations for both RUO and medical device product lines. He was most recently head of Operations & Supply Chain at Akoya Biosciences and has also held roles at Quanterix Corporation and Siemens Healthcare.
”The incredible customer interest in the Ultivue technology creates an exciting opportunity to simultaneously implement robust business systems and processes in order to scale up manufacturing and product testing in a controlled and reproducible fashion while establishing a Quality System that will meet the stringent requirements of our customers,” notes Bud.
“We’re excited for the immediate impact that Keith and Bud will have – not only for Ultivue, but also for our customers and our partners,” says Jacques Corriveau, President and CEO of Ultivue. “The combined years of expertise and industry knowledge now filling these two important roles positions us to deliver even better on our mission to help our BioPharma customers in the pursuit of advancing personalized medicine.”
Ultivue provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs.